CATEGORY

Patient Affordability

Beroe LiVE.Ai™

AI-powered self-service platform for all your sourcing decision needs across 1,600+ categories llike Patient Affordability.

Market Data, Sourcing & Supplier Intelligence, and Price & Cost Benchmarking.

Schedule a Demo

Patient Affordability Market Monitoring Dashboard

Supply Demand

Understand the correlation between costs, margins, and prices impacting your category on a real time basis on Beroe LiVE.Ai™

Patient Affordability Industry Benchmarks

Savings Achieved

(in %)

The average annual savings achieved in Patient Affordability category is 5.40%

Payment Terms

(in days)

The industry average payment terms in Patient Affordability category for the current quarter is 73.4 days

Compare your category performance against peers and industry benchmarks across 20+ parameters on Beroe LiVE.Ai™

Category Strategy and Flexibility

Engagement Model

Supply Assurance

Sourcing Process

Supplier Type

Pricing Model

Contract Length

SLAs/KPIs

Lead Time

Supplier Diversity

Targeted Savings

Risk Mitigation

Financial Risk

Sanctions

AMEs

Geopolitical Risk

Cost Optimization

Price per Unit Competitiveness

Specification Leanness

Minimum Order Quality

Payment Terms

Inventory Control

Meet Abi

The World’s first Digital Market Analyst

    Schedule a Demo
    Meet Abi

    The World’s first Digital Market Analyst

    Abi, the AI-powered digital assistant brings together data, insights, and intelligence for faster answers to sourcing questions

    Patient Affordability Suppliers

    13,471
    Total Suppliers
    393
    Diverse Suppliers
    45
    Normalized Supplier Rating
    Patient Affordability Supplier

    Find the right-fit patient affordability supplier for your specific business needs and filter by location, industry, category, revenue, certifications, and more on Beroe LiVE.Ai™.

    Sample Supplier
    Company
    IQVIA HOLDINGS INC.
    Location
    Jackson, Mississipi
    Duns number
    3862211
    D&B SER Rating
    dnb logo

    Up to 3 months

    1 9
    4
    Low Risk High Risk

    The Supplier Evaluation Risk (SER) Rating is Dun & Bradstreet’s proprietary scoring system used to assess the probability that a business will seek relief from creditors or cease operations within the next 12 months. SER ratings range from 1 to 9, with 9 indicating the highest risk of failure. We’ve prepared an infographic to help business owners better understand what influences their SER Rating.

    Moody`s ESG Solution
    ESG Profile
    Company and Sector Performance
    36
    100
    Limited (1)
    ESG Perfomance (/100)
    Environment
    41
    Social
    30
    Governance
    43
    6 Domains Performance (/100)
    Business behaviour
    48
    Human rights
    39
    Community Environment
    31
    Corporate governance
    40
    Human resources
    22
    Security Scorecard
    77
    Threat indicators
    C
    75
    Network Security
    Detecting insecure network settings
    A
    100
    Hacker Chatter
    Monitoring hacker sites for chatter about your company
    D
    63
    DNS Health
    Detecting DNS insecure configuration and vulnerabilities
    C
    70
    Application Security
    Detecting common website application vulnerbilities
    C
    77
    Endpoint Security
    Detecting unprotected enpoints or entry points of user tools, such as desktops, laptops mobile devices, and virtual desktops
    A
    100
    Cubic Score
    Proprietary algorithms checking for implementation of common security best practices
    D
    60
    Patching Cadence
    Out of date company assets which may contain vulnerabilities of risk
    A
    100
    Social Engineering
    Measuring company awareness to a social engineering or phising attack
    A
    100
    IP Reputation
    Detecting suspecious activity, such as malware or spam, within your company network
    A
    100
    Information Leak
    Potentially confidential company information which may have been inadvertently leaked
    Industry Comparison
    iqvia.com
    Industry average
    Adverse Media Appearances
    Environmental Issues
    0
    Workforce Health Safety Issues
    0
    Product Service Issues
    1
    Human Rights Issues
    0
    Production Supply Chain Issues
    0
    Environmental Non Compliance Flags
    1
    Corruption Issues
    0
    Regulatory Non Compliance Flags
    2
    Fraud Issues
    0
    Labor Health Safety Flags
    0
    Regulatory Issues
    2
    Workforce Disputes
    0
    Sanctions
    0
    esg energy transition
    28
    Discrimination Workforce Rights Issues
    0
    esg controversies critical severity
    No

    Patient Affordability market report transcript

    Global Market Outlook on Patient Affordability

    Pharmaceutical companies are increasing their reliance on patient access, affordability, and adherence programs, as they are a cost-efficient way of fulfilling marketing needs and providing marketing managers with insights into physician and patient behavior.

    Drivers
    • Stringent and changing regulations
    • Increasing government support for improving healthcare infrastructure
    • The need for reducing healthcare costs
    • Increasing volume of claims denials
    • High number of private healthcare payers and well-established government payers
    • The presence of a large number of healthcare IT companies

    Constraints

    • Slower adoption rate
    • Lack of awareness about the available access opportunities
    • Lack of denials management

    Patient Affordability Latest Market Trends

    Changing regulations in the healthcare sector is advancing the need of electronic data exchange and expanded treatment medical access. The legislation is providing amendments to lower the drug prices and simultaneously, paving the way for the bio-similars and generic drugs.

    Five-Tier Plan

    • Companies have designed a new pharmacy benefits plan, five-tier plan, where a patient can pay five different amounts of payments, depending upon the drug he/she takes
    • Five-Tier Plan: T-1: Low cost prescription drugs, T-2: Medium cost prescription drugs, T-3: High cost prescription drugs, T-4: High cost branded drugs, T-5: High cost branded and specialty drugs. Central US is pushing the payers and patients to use five tier plans

    Insurance Landscape Changes

    • Post the implementation of Affordable Care Act, the number of uninsured person has come down and is expected to go down further
    • Understanding of the reimbursement landscape can help to determine what type of support patients will need, which will reduce out-of-pocket healthcare expenses

    Co-pay Accumulators

    • Copay accumulators is a novel policy designed by PBMs and insurers to avoid using manufacturer co-pay cards, which will help in excluding copayment liabilities, covered by copay assistance programs. This will enable patients to have access to affordable prescriptions and care
    • People with employee sponsored plans and high-deductible health plans are most likely to be in co-pay accumulators plan

    Technological Advances

    • Interactive Voice Response (IVR), online patient communities are being opted by pharma in order to provide reminders and updates
    • This will indirectly improve patient adherence and provide with a wide variety of enrollment opportunities for a trial